Personalized benefit‐risk assessments combining clinical trial and real‐world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy

Purpose Quantitative benefit‐risk (B‐R) assessments are used to characterize treatment by combining key benefits and risks into a single metric but have historically been done for the “average” patient. Our aim was to conduct an individualized assessment for the oral antiplatelet vorapaxar by combining trial and real‐world data to further personalize the treatment profiles. Methods Using linked UK health care databases, we developed risk...